SpringWorks Therapeutics, part of Merck KGaA, has received conditional marketing authorization from the European Commission for its drug EZMEKLY® (mirdametinib), marking the first approved treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results